GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Common Stock

Noxopharm (ASX:NOX) Common Stock : A$74.64 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Common Stock?

Noxopharm's quarterly common stock stayed the same from Dec. 2022 (A$74.64 Mil) to Jun. 2023 (A$74.64 Mil) and stayed the same from Jun. 2023 (A$74.64 Mil) to Dec. 2023 (A$74.64 Mil).

Noxopharm's annual common stock increased from Jun. 2021 (A$72.62 Mil) to Jun. 2022 (A$74.64 Mil) but then stayed the same from Jun. 2022 (A$74.64 Mil) to Jun. 2023 (A$74.64 Mil).


Noxopharm Common Stock Historical Data

The historical data trend for Noxopharm's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Common Stock Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Common Stock
Get a 7-Day Free Trial 28.70 41.63 72.62 74.64 74.64

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.64 74.64 74.64 74.64 74.64

Noxopharm Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Noxopharm (ASX:NOX) Business Description

Traded in Other Exchanges
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines